Aspect is hosting a hands-on bioprinting session at the TERMIS-EU Workshop in Nantes, France, August 26-27.
The presentation will highlight milestone achievements to develop human liver tissue using Aspect’s microfluidic 3D bioprinting platform.
McMaster University will use the RX1 3D Bioprinter to investigate novel disease mechanisms for chronic lung diseases.
The International Society for Stem Cell Research 2019 Annual Meeting will take place June 26-29 in Los Angeles, CA.
This $2.2M project is made possible by contributions from CQDM, CCS, Merck, GSK, Aspect Biosystems, and McGill University.
CEO of Aspect Biosystems will present at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain.
Aspect collaborates with the Center for Minimally Invasive Therapies (C-MIT) at the University of California, Los Angeles (UCLA).
Connect with us at the Society for Biomaterials 2019 Annual Meeting & Exposition, April 3-6, 2019 in Seattle, WA.
Aspect will join 15 ventures from around the world in a multi-year collaboration to help align the future of work with social equity.
Aspect Biosystems Named 2019 Growth Stage Company of the Year by LifeSciences BC.
The National Research Council of Canada and Aspect Biosystems are collaborating to develop a 3D model of the blood-brain barrier.
Aspect is presenting preclinical data from recent studies focused on developing a bioprinted meniscus tissue for surgical implantation.
The Maastricht Institute for Technology-Inspired Regenerative Medicine will develop kidney tissue using an RX1™ Bioprinting Platform.
Aspect CEO and CSO visit Hong Kong for the first time to speak at the Heart Regeneration Symposium and host a seminar.
Government of Canada invests nearly $20M in top British Columbia companies in 2018.
We are attending, exhibiting, and speaking at Biofabrication, Oct 28-31, 2018 in Würzburg, Germany.